Clinical Trial News

Novo Nordisk shares fell 22% after a weight-loss drug study showed Cagrisema users lost 22.7% vs. 2.3% with a placebo, below the expected 25%. Despite this, the company plans to explore Cagrisema's potential further.

A trial suggests 'watch and wait' approach may be safe for low-risk DCIS breast cancer, potentially avoiding invasive treatments. Experts propose redefining DCIS as not cancer. Other breakthroughs include new drugs and weight-loss jabs for cancer prevention and treatment.

FDA approves Zepbound, a weight loss drug, as the first medication for sleep apnea.

The FDA approved OraQuick In-Home HIV Test for ages 14-17, expanding access for adolescents to test for HIV at home. The test detects HIV-1 and HIV-2 with an oral swab, providing results in 20 minutes, and has 99.98% specificity and 92% sensitivity. This decision aims to reduce barriers to testing and HIV spread.

HERVolution Therapeutics raised $11.7M in Series A funding led by Serum Institute of India and European Innovation Council Fund to advance HERV-targeting immunotherapies for aging-related diseases. The funding will support cGMP manufacturing, Phase 1 studies, and infrastructure expansion. HERVolution's proprietary approach breaks immune tolerance to HERVs, enabling new therapeutic applications.

Active Energy Group shares surged 309% after Zen Ventures loan and CoalSwitch plan. i-nexus Global rebounded 80% post AIM cancellation. Tiger Royalties shifts to tech incubator, acquiring Bixby for £325k. Gfinity achieved monthly profitability but delayed accounts. Nioko Resources offers 2.68p/share for Hummingbird. Tribe Technology to leave AIM, shares down 93.4%. Synairgen plans £19m raise for SNG001 study. Cadence Minerals to acquire tungsten licences. Webis and Neometals to leave AIM.

The FDA approved Zepbound, a weight-loss drug, for treating moderate to severe obstructive sleep apnea in obese individuals. It should be used with a reduced-calorie diet and increased physical activity. Clinical trials showed significant improvements in sleep apnea symptoms and weight loss.

Sat, December 21, 2024 at 9:17 AM UTC

Researchers identified three unique subtypes of osteosarcoma using Latent Process Decomposition, potentially transforming clinical trials and patient care by enabling targeted treatments.

US FDA approves Zepbound, a weight-loss drug by Eli Lilly, for treating moderate to severe obstructive sleep apnea (OSA) in obese adults. Zepbound works by reducing appetite and food intake, improving OSA through weight loss. It is administered weekly with exercise and a reduced-calorie diet.